TY - JOUR
T1 - Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma
AU - Tagawa, Hiroyuki
AU - Suguro, Miyuki
AU - Tsuzuki, Shinobu
AU - Matsuo, Keitaro
AU - Karnan, Sivasundaram
AU - Ohshima, Koichi
AU - Okamoto, Masataka
AU - Morishima, Yasuo
AU - Nakamura, Shigeo
AU - Seto, Masao
PY - 2005/9/1
Y1 - 2005/9/1
N2 - Diffuse large B-cell lymphoma (DLBCL) comprises molecularly distinct subgroups such as activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCLs. We previously reported that CD5+ and CD5 -CD10+ DLBCL constitute clinically relevant subgroups. To determine whether these 2 subgroups are related to ABC and GCB DLBCLs, we analyzed the genomic imbalance of 99 cases (36 CD5+, 19 CD5 -CD10+, and 44 CD5-CD10-) using array-based comparative genomic hybridization (CGH). Forty-six of these cases (22 CD5+, 7 CD5-CD10+, and 17 CD5 -CD10-) were subsequently subjected to gene-expression profiling, resulting in their division into 28 ABC (19 CD5+ and 9 CD5-CD10-) and 18 GCB (3 CD5+, 7 CD5 -CD10+, and 8 CD5-CD10-) types. A comparison of genome profiles of distinct subgroups of DLBCL demonstrated that (1) ABC DLBCL is characterized by gain of 3q, 18q, and 19q and loss of 6q and 9p21, and GCB DLBCL is characterized by gain of 1q, 2p, 7q, and 12q; (2) the genomic imbalances characteristic of the CD5+ and CD5 -CD10+ groups were similar to those of the ABC and GCB types, respectively. These findings suggest that CD5+ and CD5 -CD10+ subgroups are included, respectively, in the ABC and GCB types. Finally, when searching for genomic imbalances that affect patients' prognosis, we found that 9p21 loss (p16INK4a locus) marks the most aggressive type of DLBCL.
AB - Diffuse large B-cell lymphoma (DLBCL) comprises molecularly distinct subgroups such as activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCLs. We previously reported that CD5+ and CD5 -CD10+ DLBCL constitute clinically relevant subgroups. To determine whether these 2 subgroups are related to ABC and GCB DLBCLs, we analyzed the genomic imbalance of 99 cases (36 CD5+, 19 CD5 -CD10+, and 44 CD5-CD10-) using array-based comparative genomic hybridization (CGH). Forty-six of these cases (22 CD5+, 7 CD5-CD10+, and 17 CD5 -CD10-) were subsequently subjected to gene-expression profiling, resulting in their division into 28 ABC (19 CD5+ and 9 CD5-CD10-) and 18 GCB (3 CD5+, 7 CD5 -CD10+, and 8 CD5-CD10-) types. A comparison of genome profiles of distinct subgroups of DLBCL demonstrated that (1) ABC DLBCL is characterized by gain of 3q, 18q, and 19q and loss of 6q and 9p21, and GCB DLBCL is characterized by gain of 1q, 2p, 7q, and 12q; (2) the genomic imbalances characteristic of the CD5+ and CD5 -CD10+ groups were similar to those of the ABC and GCB types, respectively. These findings suggest that CD5+ and CD5 -CD10+ subgroups are included, respectively, in the ABC and GCB types. Finally, when searching for genomic imbalances that affect patients' prognosis, we found that 9p21 loss (p16INK4a locus) marks the most aggressive type of DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=23944468557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23944468557&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-02-0542
DO - 10.1182/blood-2005-02-0542
M3 - Article
C2 - 15886317
AN - SCOPUS:23944468557
SN - 0006-4971
VL - 106
SP - 1770
EP - 1777
JO - Blood
JF - Blood
IS - 5
ER -